Chelation Therapy: Side Effects, Risks and Mineral Loss
Mineral loss, redistribution and the EDTA deaths honestly sorted out. And the question that really counts: harmless, warning sign or emergency?
A focus area at ViveCura: chelation therapy with full safety monitoring
Heavy-metal chelation is one of my focus areas. Precisely because chelation therapy is a pharmacological intervention, I take safety as seriously as efficacy. This article is my attempt neither to play down the risks for you nor to scare you off across the board. Instead, to explain them so that you can make an informed decision.
Why you ask about the risks first
Many people who are thinking about heavy-metal chelation do not first google "how does it work" but "what can go wrong". That is not a sign of anxiety. It is common sense. You have read in forums about mineral loss, about an alleged redistribution into the brain, perhaps even about deaths. And now you stand between fear and hope.
I want to be honest with you: the risks are real. But they are nameable, classifiable and, in most cases, controllable. This is exactly what makes the public debate around chelation side effects so unsatisfying. One side says "harmless and natural". The other side says "life-threatening and quackery". Both ignore the decisive variable.
The chelating agent is not the actual risk; the missing protocol behind it is. Chelation therapy is neither inherently dangerous nor inherently harmless. It is a pharmacological intervention that is exactly as safe as the system behind it works cleanly.
Most real harm does not arise from the molecule itself, but from missing mineral monitoring, the wrong EDTA form, too high a dose without breaks, or self-medication without diagnostics. Risk here is less a property of the molecule than a property of diligence.
The mechanism of chelation therapy, that is, how a chelating agent grips a metal in a pincer-like hold and flushes it out via the kidney, is explained in the overarching heavy-metals guide. Here it is exclusively about the safety dimension.
Harmless, warning sign or emergency? The triage
Anyone who undergoes chelation therapy knows the feeling of interpreting every bodily sensation afterwards. Is the fatigue normal? Is the metallic taste a bad sign? This is exactly where typical online information fails. Package inserts list everything as equally weighted. Practice websites prefer to keep quiet. Nobody sorts.
That is why I start with the most important thing: a triage. It does not replace a medical assessment, but it gives you a grid with which you can classify sensations instead of swinging between trivialisation and panic.
| Usually harmless & transient | Warning sign: have it checked | Emergency: stop immediately |
|---|---|---|
| Mild fatigue on the day of infusionObserve, rest | Newly appearing skin rashClarify before next dose | Shortness of breath, tightness in the throatCall emergency services at once |
| Metallic taste in the mouthNo action needed | Persistent fever, chillsContact your doctor | Swelling of lips, tongue, faceCall emergency services at once |
| Temporary headachesDrink fluids, observe | Muscle cramps, tingling (calcium?)Have electrolytes checked | Circulatory collapse, clouded consciousnessCall emergency services at once |
| Mild malaise after a doseObserve | Unusual tendency to bleed, bruisingCheck blood count | Rapidly blistering rashStop, see a doctor at once |
A skin rash is the most common visible sign and usually harmless. In rare cases, however, it can be the start of a severe hypersensitivity reaction. That is why it belongs in the middle column: not panic, but clarify before the next dose follows. Muscle cramps and tingling can point to a shift in the calcium or mineral balance. That is the reason why a good protocol does not first react once symptoms are present, but measures beforehand.
In the TLC study, the largest randomised investigation of oral succimer in children, an increased scalp rash was the most striking side effect. That puts the triage in perspective: skin reactions are common, severe reactions rare.
Who: Toddlers with blood lead of 20 to 44 µg/dl; the safety and efficacy of succimer was systematically recorded.
What: More scalp rashes under succimer (3.5 versus 1.3 percent), otherwise few side effects.
What this means for you: Skin reactions are the most common visible side effect and a point a protocol should actively watch.
TLC Trial Group. Safety and efficacy of succimer in toddlers with blood lead levels of 20-44 µg/dL. Pediatr Res. 2000;48(5):593-9. DOI: 10.1203/00006450-200011000-00007Mineral loss, the best-documented risk
If you want to name a real, measurable side effect of chelation therapy, it is not poisoning by the chelating agent. It is the loss of essential trace elements. And this is also the point where serious and dubious practice differ most clearly.
The mechanism: why a chelating agent does not only grab poison
A chelating agent does not draw a moral distinction between "toxic" and "vital" metal. It binds according to chemical affinity. That is why DMPS pulls along not only mercury but also copper, zinc and magnesium. Viewed through the lens of functional medicine, this is decisive: these minerals are cofactors in hundreds of enzymes. Zinc is involved in immune defence and wound healing, copper in energy production, magnesium in muscle and nerve function.
Who: Trace elements in urine measured before and after intravenous DMPS in humans.
What: Copper excretion increased 2- to 119-fold, selenium 3- to 43.8-fold, zinc 1.6- to 44-fold, magnesium up to 42.7-fold. Manganese, chromium and cobalt remained unchanged.
What this means for you: DMPS measurably pulls along important minerals too. This is precisely why zinc, copper and magnesium belong in the monitoring.
Torres-Alanis O et al. Urinary excretion of trace elements in humans after DMPS challenge test. J Toxicol Clin Toxicol. 2000;38(7):697-700. DOI: 10.1081/clt-100102382This range, some values increased 119-fold, sounds dramatic. But it concerns a single challenge, not a permanent state. The question is never "do I lose minerals" but "is the loss monitored and balanced out". Which minerals should be kept under particular watch is shown in this overview.
Zinc
Cofactor for the immune system, skin and wound healing. A deficit can show up as frequent infections, taste disturbances or poor wound healing.
Copper
Important for energy production and connective tissue. It is excreted most strongly under DMPS, so it should be watched closely.
Magnesium
Central to muscle and nerve function. A deficiency can manifest as cramps, tingling or inner restlessness.
Selenium
A building block of the body's own antioxidant defence. It is also excreted in increased amounts and is relevant for detoxification capacity.
Why accompanying substitution makes mechanistic sense
Here it is worth a look at the animal model, clearly labelled as such. An animal study in lead-poisoned rats investigated what happens when zinc and copper are given alongside the chelation dose.
Who: Zinc and copper supplementation during chelation in lead-poisoned rats was investigated.
What: The simultaneous administration of zinc and copper reversed the depleted mineral status more effectively and at the same time increased lead excretion.
What this means for you: A mechanistic support for why accompanying, cyclical mineral substitution can make sense. Transfer to humans with reservation, because it is an animal study.
Flora SJ. Influence of simultaneous supplementation of zinc and copper during chelation of lead in rats. Hum Exp Toxicol. 1991;10(5):331-6. DOI: 10.1177/096032719101000506This is put into mechanistic context by two review articles that describe the connection between substance choice and mineral loss in principle.
Who: The physicochemical foundations of metal-chelate binding and distribution were worked through.
What: The metal selectivity of a chelating agent is important, precisely because of the danger of depleting essential metals.
What this means for you: Explains why substance choice and mineral loss are directly connected.
Andersen O. Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004;4(1):11-21. DOI: 10.2174/1389557043487583A careful protocol measures the relevant minerals before the start and during the course, instead of chelating blindly. During the breaks between cycles, what is lost in increased amounts is replaced. Symptoms such as cramps, frequent infections or persistent exhaustion are not a footnote but clues that I take seriously and hold against the lab values.
I deliberately do not describe any specific dosages or weekly schedules here. Substitution schemes are not standardised in the primary literature; they belong in individual medical assessment and not as a copyable recipe in a blog. How the mineral balance is measured in principle is explored in depth in the article on the DMPS challenge test, which uses the same mobilisation.
Redistribution, the myth and the true core
Hardly any term appears as often in critical forums as "redistribution". What is meant is the concern that a chelating agent mobilises mercury from the body and then redistributes it, of all places, into the brain, that is, exactly where it could do the most damage. This fear is often used as a knockout argument. It deserves an honest, differentiated answer.
The term has a real core, but it stems mostly from data on the older, fat-soluble chelators such as BAL (dimercaprol) and partly EDTA. Fat-soluble substances can cross membranes more easily and potentially shift a metal into nerve tissue as well.
The modern chelators DMPS and DMSA, by contrast, are water-soluble (hydrophilic). According to the available review articles, they barely cross the blood-brain barrier. Applying the term across the board to all chelators conflates two very different classes of substance.
Who: The role of BAL, DMPS and DMSA in arsenic and mercury poisoning was summarised.
What: According to this review, DMPS and DMSA have a higher therapeutic index than BAL and do not redistribute arsenic or mercury into the brain.
What this means for you: The redistribution accusation applies above all to the old chelators, not necessarily to the modern dithiols.
Kosnett MJ. The role of chelation in the treatment of arsenic and mercury poisoning. J Med Toxicol. 2013;9(4):347-54. DOI: 10.1007/s13181-013-0344-5Who: Updated principles on the use of chelating agents were presented.
What: EDTA and BAL are limited in their use by their own toxicity and the tendency to increase the neurotoxicity of some metals. DMSA and DMPS are considered less toxic and are orally available.
What this means for you: Supports the distinction that older chelators are riskier than the modern ones.
Aaseth J et al. Chelation in metal intoxication, principles and paradigms. J Trace Elem Med Biol. 2014;31:260-6. DOI: 10.1016/j.jtemb.2014.10.001Through the lens of toxicology, a further point puts the fear into perspective: inorganic mercury crosses the blood-brain barrier only poorly in any case. A review on mercury poisoning from cosmetics describes this.
Who: Mercury poisoning from skin-lightening cosmetics and its treatment was summarised.
What: The penetration of the blood-brain barrier by inorganic mercury is low. DMPS is regarded as the preferred antidote; DMSA was also used.
What this means for you: Puts the redistribution fear into perspective, because inorganic mercury crosses the barrier poorly anyway.
Chan TY. Inorganic mercury poisoning associated with skin-lightening cosmetic products. Clin Toxicol (Phila). 2011;49(10):886-91. DOI: 10.3109/15563650.2011.626425And yet: the true core remains. In one animal study, DMSA even chelated lead out of the brain without visible damage occurring. That is encouraging, but it is an animal study. When does redistribution become real? Mechanistically, when the dose is too high, breaks are missing, or a fat-soluble substance is used without indication. That is, once again, a question of the protocol, not of the principle.
The statements on redistribution rest mostly on review articles and animal data. A direct human comparison of brain redistribution under DMSA or DMPS against the older chelators is missing. That, honestly, is an evidence gap. Where I speak from clinical experience, I mark it as such and not as a proven fact.
Why people have died from EDTA
This is the point where many sceptic texts play their strongest card: there are documented deaths. That is true. And precisely because it is true, I want to explain the exact mechanism to you, rather than dramatising or downplaying it. Because whoever understands the mechanism can ask the right question.
There are two forms of EDTA that can be fatally confused. Calcium disodium EDTA (CaNa₂EDTA) brings its own calcium with it. Edetate disodium (Na₂EDTA) does not, and instead binds calcium from the blood. If the wrong form, that is Na₂EDTA, is infused quickly, the calcium level in the blood can drop dangerously. This hypocalcaemia can trigger cardiac arrest.
The three documented deaths in the USA between 2003 and 2005 arose in exactly this way: from confusing the EDTA form, not from the effect of chelation itself.
Who: Three deaths reported to the CDC due to cardiac arrest from hypocalcaemia during chelation therapy were analysed.
What: Two of the three cases were children, both treated with edetate disodium. The recommendation was to stock less toxic alternatives.
What this means for you: The deaths hinge on a substance mix-up, not on chelation per se.
Brown MJ et al. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006;118(2):e534-6. DOI: 10.1542/peds.2006-0858Who: The death of a 5-year-old boy during EDTA chelation was documented.
What: Edetate disodium was accidentally given instead of calcium disodium EDTA, which triggered severe hypocalcaemia and cardiac arrest.
What this means for you: The EDTA form is safety-critical. Ensuring the correct form is a concrete, answerable question of practice.
Baxter AJ, Krenzelok EP. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila). 2008;46(10):1083-4. DOI: 10.1080/15563650701261488Allergy and blood count, the risks that require monitoring
Besides mineral loss, there is a second group of real side effects that a protocol must keep an eye on: allergic reactions and changes in the blood count. These are rarer, but they are the reason why chelation therapy belongs under medical supervision and should not take place on your own at home.
Who: DMPS alternating with penicillamine in Wilson's disease was observed over up to five years.
What: Side effects under intravenous DMPS were above all neutropenia, thrombocytopenia, allergic reaction and tendency to bleed.
What this means for you: Blood count and signs of allergy are among the risks that require monitoring under DMPS.
Xu SQ et al. Clinical efficacy and safety of chelation treatment with penicillamine combined with DMPS for Wilson's disease. J Huazhong Univ Sci Technolog Med Sci. 2013;33(5):743-7. DOI: 10.1007/s11596-013-1190-zThe good news from the same indication: with accompanying monitoring and zinc administration, DMPS can show a stable safety picture.
Who: DMPS plus zinc versus D-penicillamine in neurological Wilson's disease was compared over one year.
What: In the DMPS-plus-zinc group, kidney function, liver enzymes and blood count remained stable, with a higher rate of improvement than under penicillamine.
What this means for you: With accompanying zinc administration and monitoring, DMPS can show a stable safety profile.
Zhang J et al. Combined sodium dimercaptopropanesulfonate and zinc versus D-penicillamine for neurological Wilson's disease. BMC Neurol. 2020;20(1):255. DOI: 10.1186/s12883-020-01827-9For the oral chelating agent DMSA, an overall favourable but not risk-free profile applies. A temporary rise in liver values has been described. The details on the oral DMSA profile can be found in the article on DMSA; here only the classification.
Who: The safety profile of DMSA in children was worked through.
What: The profile is favourable with few clinical or biochemical side effects, but it does not rule out hypersensitivity or idiosyncratic reactions.
What this means for you: Even a favourable profile does not mean zero risk. Allergic reactions remain possible.
Glotzer DE. The current role of DMSA in the management of childhood lead poisoning. Drug Saf. 1993;9(2):85-92. DOI: 10.2165/00002018-199309020-00002Who should NOT chelate, the contraindications
This is the section that practice websites with a sales motive most often leave out. Yet it is the actual proof of seriousness. Honest information about contraindications is more important than any sale. Because chelation therapy temporarily burdens the excretory and metabolic pathways, and there are situations in which exactly that can become dangerous.
Situations that argue against chelation therapy or call for special caution
- Impaired kidney function: The mobilised metals are excreted via the kidney. With a pre-damaged kidney, this can increase the burden. The kidney values therefore belong checked before and during the therapy.
- Pregnancy and breastfeeding: Mobilised metals and the intervention in the mineral balance can affect the unborn or breastfed child. Special restraint is called for here. More on this in the article on heavy metals in pregnancy and in children.
- Known allergy to the chelating agent: A previous allergic reaction is a clear exclusion criterion for the same substance.
- Unstable mineral balance: Anyone who already has a pronounced deficiency of zinc, magnesium or calcium should stabilise this first. Otherwise the therapy reinforces an existing deficit.
- Acute illness or unstable circulation: In acute phases of illness, the body is occupied with other things. An elective chelation can wait.
Whoever names the risks honestly controls them. Whoever conceals them or condemns them across the board gets you nowhere.
Herxheimer or a genuine side effect?
In forums, two completely different things are constantly confused: the so-called initial worsening and a genuine side effect. This distinction is not academic. It is safety-relevant, because it decides whether you observe or stop.
The term Herxheimer reaction originally comes from the treatment of infections and describes a temporary feeling of being worse when the body has to deal with released substances. In the context of chelation, it is often used loosely for a general malaise after a dose. That can be harmless. The problem arises when genuine warning signs are dismissed as "just Herxheimer".
Fatigue, mild malaise or a dull feeling that subsides after hours to a day or two is rather uncritical and can be observed. Signs of allergy such as rash, itching, swelling, plus shortness of breath, fever or circulatory problems are not an expected part of the process. They are a stop signal and belong checked by a doctor.
I will say it honestly: there is no hard, controlled study that cleanly defines this distinction for chelation therapy. It remains a clinical triage. This is exactly why chelation therapy belongs in supervised hands and not in self-medication, where nobody is there to distinguish for you between "process" and "stop signal". This also applies to supposedly gentle routes: even a thoughtless natural chelation without a plan can mobilise without safely excreting.
Chelation is not an end in itself
An honest safety article must also talk about the other side: the benefit. Because the most important safety argument is sometimes not to begin a therapy at all without a clear indication. A treatment that achieves nothing has a poor risk-to-benefit ratio, even if the side effects are minor.
Who: Up to three oral succimer courses versus placebo in toddlers with blood lead of 20 to 44 µg/dl, follow-up over 36 months.
What: Succimer lowered the blood lead level (by 4.5 µg/dl lower on average) but produced no statistically significant benefit in IQ, behaviour or neuropsychology.
What this means for you: Lowering blood values is not the same as producing a benefit. Chelation only makes sense with a clear indication.
Rogan WJ et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344(19):1421-6. DOI: 10.1056/NEJM200105103441902Who: Long-term follow-up of the same cohort up to school entry.
What: Succimer lowered blood lead for around six months but produced no benefit in cognitive, behavioural and neuromotor endpoints.
What this means for you: Confirms over the long term that at moderately elevated levels, removing the source can be more important than chelation.
Dietrich KN et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics. 2004;114(1):19-26. DOI: 10.1542/peds.114.1.19That sounds sobering at first, but it is a central part of the honest middle ground: a controlled application has relatively few side effects, but it is not a cure-all. Through the lens of classical toxicology, the indication is decisive. One review names the three core risks openly.
Who: The drawbacks of classical chelators and alternatives were summarised.
What: Metal chelators can have drawbacks such as a redistribution of some heavy metals into the brain, the loss of essential metals such as copper and zinc, and a burden on the liver.
What this means for you: Names honestly the three core risks that a good protocol specifically addresses.
Amadi CN et al. Natural antidotes and management of metal toxicity. Environ Sci Pollut Res Int. 2019;26(18):18032-52. DOI: 10.1007/s11356-019-05104-2Risk is a property of diligence
If you summarise the evidence, a clear pattern emerges: most real harm hinges on four controllable levers. The right substance form instead of a mix-up. Mineral monitoring instead of blind chelation. An appropriate dose with breaks instead of overdosing. And the correct indication instead of therapy on suspicion.
None of these levers lies in the molecule. All of them lie in the protocol. This is exactly why naming the risks honestly is not an argument against chelation therapy, but the prerequisite for making it safe.
4How a careful protocol controls risks
Without providing a copyable scheme, the logic can be described in one direction: first diagnose, then prepare the ground, then work in cycles with breaks, and measure throughout. Anyone who wants to understand the exact course of a serious chelation therapy will find it in the article on the process, duration and what to expect. That one is about the process; this one was about the risks within that process.
| Statement | State of evidence | Limitation |
|---|---|---|
| DMPS increases the excretion of zinc, copper, selenium, magnesium | Documented in humans | Range highly individually variable; concerns a single dose, not a permanent state |
| Modern dithiols (DMPS/DMSA) do not redistribute Hg/As into the brain | Reviews + animal data | Direct human comparison missing; transparency disclaimer |
| EDTA deaths from Na₂EDTA mix-up | Pharmacovigilance (CDC) | Process and mix-up risk, not a molecular risk |
| DMPS: neutropenia, thrombocytopenia, allergy possible | Clinical cohorts | Requires monitoring; stable with monitoring |
| Accompanying zinc/copper administration mitigates mineral depletion | Animal model | Transfer to humans with reservation |
| Succimer lowers blood lead, but no cognitive benefit at moderate burden | Large RCT (n=780) | Applies to moderately elevated levels; indication decisive |
| Herxheimer vs. genuine side effect | Clinical triage | No controlled study on the distinction; medical assessment |
And now you know why the question "is chelation therapy dangerous" so rarely gets an honest answer. Because the honest answer is: it depends on how carefully it is done.
Frequently asked questions about side effects and risks
Which chelation therapy side effects are harmless and which are an emergency?
What is redistribution and is the fear of it shifting into the brain justified?
Do you lose important minerals during chelation therapy?
Why have people died from EDTA?
Who should not undergo chelation therapy?
Is an initial worsening (Herxheimer) normal?
How dangerous is DMPS really?
Can you carry out chelation therapy yourself at home?
Does chelation therapy cause liver damage?
Does chelation therapy always provide a health benefit?
Read on in the heavy-metals guide
This article is part of a larger guide. If you want to go deeper, these articles lead on to the adjacent questions.
Heavy Metals: What Really Sits in Your Body
The overarching guide: sources, mechanisms, diagnostics and the logic of chelation.
PillarChelation Therapy: The Process, Duration and What to Expect
The process step by step: from diagnostics to the cycles.
EDTA Chelation Therapy: Lead, Calcium and Blood Vessels
Why the EDTA form is safety-critical and what EDTA is used for specifically.
DMSA: the oral chelating agent in detail
The oral profile, the liver values and what DMSA is particularly suited for.
DMPS mobilisation test: measuring correctly
How the challenge test works and why it also mobilises minerals.
Natural Heavy-Metal Chelation
Chlorella, coriander, wild garlic: possibilities, limits and the mobilisation trap.
The data on mineral loss, EDTA deaths and clinical side effects rest on human studies, pharmacovigilance data and clinical cohorts. The statements on redistribution into the brain rest mostly on review articles and animal data; a direct human comparison is missing and is marked as such. This article does not replace medical advice. It describes mechanisms and risks, not a copyable treatment protocol. Chelation therapy should be medically supervised and weighed up individually.
Scientific Sources
- Rogan WJ, Dietrich KN, Ware JH et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344(19):1421-6. DOI: 10.1056/NEJM200105103441902 [RCT, n=780]
- Dietrich KN, Ware JH, Salganik M et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics. 2004;114(1):19-26. DOI: 10.1542/peds.114.1.19 [RCT follow-up, n=647]
- Treatment of Lead-Exposed Children (TLC) Trial Group. Safety and efficacy of succimer in toddlers with blood lead levels of 20-44 µg/dL. Pediatr Res. 2000;48(5):593-9. DOI: 10.1203/00006450-200011000-00007 [RCT, n=780]
- Torres-Alanis O, Garza-Ocanas L, Bernal MA, Pineyro-Lopez A. Urinary excretion of trace elements in humans after sodium DMPS challenge test. J Toxicol Clin Toxicol. 2000;38(7):697-700. DOI: 10.1081/clt-100102382 [Human, n=11]
- Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006;118(2):e534-6. DOI: 10.1542/peds.2006-0858 [CDC case series, n=3]
- Baxter AJ, Krenzelok EP. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila). 2008;46(10):1083-4. DOI: 10.1080/15563650701261488 [Case report]
- Kosnett MJ. The role of chelation in the treatment of arsenic and mercury poisoning. J Med Toxicol. 2013;9(4):347-54. DOI: 10.1007/s13181-013-0344-5 [Review]
- Andersen O. Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004;4(1):11-21. DOI: 10.2174/1389557043487583 [Mechanism review]
- Aaseth J, Skaug MA, Cao Y, Andersen O. Chelation in metal intoxication, principles and paradigms. J Trace Elem Med Biol. 2014;31:260-6. DOI: 10.1016/j.jtemb.2014.10.001 [Review]
- Amadi CN, Offor SJ, Frazzoli C, Orisakwe OE. Natural antidotes and management of metal toxicity. Environ Sci Pollut Res Int. 2019;26(18):18032-52. DOI: 10.1007/s11356-019-05104-2 [Review]
- Glotzer DE. The current role of DMSA in the management of childhood lead poisoning. Drug Saf. 1993;9(2):85-92. DOI: 10.2165/00002018-199309020-00002 [Safety review]
- Aposhian HV, Maiorino RM, Gonzalez-Ramirez D et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology. 1995;97(1-3):23-38. DOI: 10.1016/0300-483x(95)02965-b [Mechanism review]
- Xu SQ, Li XF, Zhu HY et al. Clinical efficacy and safety of chelation treatment with penicillamine combined with DMPS for Wilson's disease. J Huazhong Univ Sci Technolog Med Sci. 2013;33(5):743-7. DOI: 10.1007/s11596-013-1190-z [Clinical cohort, n=35]
- Zhang J, Xiao L, Yang W. Combined sodium dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease. BMC Neurol. 2020;20(1):255. DOI: 10.1186/s12883-020-01827-9 [Retrospective cohort, n=158]
- Flora SJ. Influence of simultaneous supplementation of zinc and copper during chelation of lead in rats. Hum Exp Toxicol. 1991;10(5):331-6. DOI: 10.1177/096032719101000506 [In vivo, rat]
- Chan TY. Inorganic mercury poisoning associated with skin-lightening cosmetic products. Clin Toxicol (Phila). 2011;49(10):886-91. DOI: 10.3109/15563650.2011.626425 [Review]